GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coegin Pharma (NGM:COEGIN) » Definitions » EV-to-EBIT

Coegin Pharma (NGM:COEGIN) EV-to-EBIT : -3.12 (As of May. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Coegin Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Coegin Pharma's Enterprise Value is kr87.22 Mil. Coegin Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-27.96 Mil. Therefore, Coegin Pharma's EV-to-EBIT for today is -3.12.

The historical rank and industry rank for Coegin Pharma's EV-to-EBIT or its related term are showing as below:

NGM:COEGIN' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.52   Med: -0.07   Max: 0.01
Current: -3.12

During the past 7 years, the highest EV-to-EBIT of Coegin Pharma was 0.01. The lowest was -3.52. And the median was -0.07.

NGM:COEGIN's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 10.43 vs NGM:COEGIN: -3.12

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Coegin Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was kr45.01 Mil. Coegin Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-27.96 Mil. Coegin Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -62.11%.


Coegin Pharma EV-to-EBIT Historical Data

The historical data trend for Coegin Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coegin Pharma EV-to-EBIT Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial -0.96 -2.58 -7.45 -2.65 -1.61

Coegin Pharma Quarterly Data
Dec18 Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.65 -4.06 -2.86 -2.25 -1.61

Competitive Comparison of Coegin Pharma's EV-to-EBIT

For the Biotechnology subindustry, Coegin Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coegin Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's EV-to-EBIT falls into.



Coegin Pharma EV-to-EBIT Calculation

Coegin Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=87.216/-27.959
=-3.12

Coegin Pharma's current Enterprise Value is kr87.22 Mil.
Coegin Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-27.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coegin Pharma  (NGM:COEGIN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Coegin Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-27.959/45.012505205
=-62.11 %

Coegin Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was kr45.01 Mil.
Coegin Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-27.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coegin Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Coegin Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Coegin Pharma (NGM:COEGIN) Business Description

Traded in Other Exchanges
N/A
Address
Birger Jarlsgatan 18 A, 4th Floor, Stockholm, SWE, 114 34
Coegin Pharma AB is a biotechnology company that focuses on the development of small molecule therapies for the treatment of inflammatory diseases such as cancer and kidney disease.

Coegin Pharma (NGM:COEGIN) Headlines

No Headlines